China Energy Storage Technology Development Limited — Capital/Financing Update 2021

May 19, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 46] intentionally omitted <==

Link-Asia International MedTech Group Limited 環 亞 國 際 醫 療 科 技 集 團 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO THE INVESTMENT COOPERATION MEMORANDUM

This announcement is made on a voluntary basis by Link-Asia International MedTech Group Limited (the “ Company ”, together with its subsidiaries, the “ Group ”) on a voluntary basis to provide the shareholders (the “ Shareholders ”) and potential investors of the Company with updated information in relation to the latest business development of the Group.

THE INVESTMENT COOPERATION MEMORANDUM

The board (the “ Board ”) of directors (the “ Director(s) ”) of the Company is pleased to announce that, on 19 May 2021, Link-Asia International Assisted Reproductive Technology Group Limited* ( 環亞國際辅助生殖科技集團有限公司 ) (“ Assisted Reproductive Technology ”), which is a wholly-owned subsidiary of the Company, entered into a non-legally binding investment cooperation memorandum (the “ Memorandum ”) with Fujian Nuoyike Bio Technology limited* ( 福建诺医可生物科技有限公司 ) (the “ Nuoyike ”) , pursuant to which the parties to the Memorandum agreed to cooperate and form a joint venture company (the “ JV Company ”) for the purpose of building marketing and promotion pipeline system of ‘‘assisted reproduction plus medical cosmetology’’ consumer medical services and related products (the “ Possible Investment Cooperation ”).

According to the Memorandum, Assisted Reproductive Technology will hold majority of the equity interests in the JV Company upon completion of its formation. Besides, the team from Nuoyike will be responsible for the daily operation and management of the JV Company.

Pursuant to the Memorandum, Assisted Reproductive Technology shall conduct a due diligence review, which is to be completed within 90 days from the date of signing of the Memorandum, on Nuoyike. Subject to the results of the aforesaid due diligence review being satisfied to Assisted Reproductive Technology, Assisted Reproductive Technology and Nuoyike shall use their best endeavors to enter into formal investment cooperation agreement to stipulate the details.

INFORMATION ABOUT NUOYIKE

Nuoyike is a company established in the People’s Republic of China（the “ PRC ”） with limited liability and the principal business is promoting and selling medical beauty products.

According to the information provided by Nuoyike, as at the date of the announcement, it is owned by two individuals, namely Ms. Jin Lu (“ Ms. Jin ”) and Ms. Su Huijuan, holding 96% and 4% equity interests, respectively. Ms Jin has around 15 years of experience in the medical cosmetic industry.

Save as disclosed, to the best of knowledge, information and belief of the Directors having made all reasonable inquiries, Nuoyike and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “ Listing Rules ”)).

REASONS FOR AND BENEFITS OF THE POSSIBLE COOPERATION

The Group is principally engaged in (i) electronic manufacturing services; (ii) marketing and distribution of communication products; (iii) real estate supply chain services; (iv) assisted reproduction medical technology business; and (v) the securities and other assets investment.

The Board and the management of the Company are not only dedicated to developing the Group’s existing core businesses but are also actively exploring and deploying new business, especially the assisted reproduction medical technology business with huge market demand.

The team from Noyiko has developed more than one thousand channels in medical cosmetic industry since its establishment, demonstrating its strong marketing and channel integration ability. The Board believes that if both parties can jointly build the new business form of "assisted reproduction plus medical cosmetology", it can not only broaden the access channels to obtain the customers for the Company's assisted reproduction business, but also bring accurate customer bases for the Company. In the long run, it is helpful to improve the profitability of the Company and maximise the interests of the Company and its shareholders.

GENERAL INFORMATION

The Board wishes to emphasize that as at the date of this announcement, the Company has not entered into a binding agreement in relation to the Possible Investment Cooperation. The Possible Investment Cooperation, if materialised, may constitute a notifiable transaction for the Company under the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and other investors of the Company should note that the Possible Investment Cooperation may or may not proceed and are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board Link-Asia International MedTech Group Limited

Lin Dailian Chairman and executive Director

Hong Kong, 19 May 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu and Mr. Yang Weidong as independent non-executive Directors.

* For identification purposes only